Académique Documents
Professionnel Documents
Culture Documents
Welcome
1st October, 2013 Inside This Issue
Welcome New faces! New PhDs! Funding Opportunities Hot off the Press RPS Conference UKPS Conference Clinical Trials
The newsletter is published monthly during term time. This issue covers the period September 2013. Please let Cat Hale (c.hale@reading.ac.uk) know if there are items you would like included in the next issue. We aim to report successful grant applications, published papers, and related research news. The deadline for the next newsletter is October th 26 , 2013
#17
New faces!
We have a number of new faces joining the RSOP team this month ! Firstly, Academic Investment Post appointees, Dr Angela Bithell and Dr Patrick Lewis join the Pharmacology Division and are based in the Hopkins Building. Also joining the team in Hopkins is Dr Alistair Nunn, who takes up his role within the new Associate Professorship created within RSOP by a 240,000 donation from GW Pharmaceuticals. Finally, Dr Sandra Tejero, who previously worked in Food and Nutritional Sciences, joins Dr Al Edwardss lab to work on his microcapillary diagnostics technology with CFT Ltd.
Dr Nunn, RSOPs new Associate Professor in Hormesis and Metabolic Adaptation settles in.
New PhDs!
RSOPs PhD student numbers are swelled by three new starters this month! Hesham Abduldaeem will be working with Dr Parastou Donyai and Dr Rosemary Lim on a project funded by the Saudi Armed Forces, Medical Services. Rebecca Thomson will be working with Prof. Helen Osborn and Dr Katja Strohfeldt-Venables on a project co-funded by the BBSRC and Ludger whilst Sarah Smith joins Dr Vitaliy Khutoryanskiys group to work on a project jointly funded by the BBSRC and McCormick. Finally, Ariane Thrun joins Dr Gary Stephens and Dr Ben Whalley to work on a project jointly funded by UoR and UCB Pharmaceuticals
Funding Opportunities
Grant opportunities see Funding news on the University Web pages. Studentship opportunities have their own page. These pages list numerous opportunities for grants and studentships, as well as the deadlines. Research Professional Online is a searchable source of funding opportunities and research news. University PhD Studentship Competition 2014 The application process for the annual University Studentships competition is now open. Updates on the number of available half studentships will be circulated as soon as the information is received from Faculty. University funding will cover 50% of Home/EU fees for three years, 50% of the student stipend at RCUK minimum doctoral stipend levels for three years and 500 per annum to cover personal development costs (training courses, conferences, etc.). Full details of the call can be obtained from Cat Hale (c.hale@reading.ac.uk). Please note that the remaining 50% of the funds required for these studentships must be met externally and must be agreed at the time the application is made.
Dr Patrick Lewis has highlighted the forthcoming Keystone meeting in March 2014 on Parkinsons Disease: Genetics, Mechanisms and Therapeutics which may be of interest to our burgeoning neurodegeneration specialisation. Details are available here: http://www.keystonesy mposia.org/14Q7
Dr Gary Stephens has joined the Calcium Channel Network (http://www.calciumch annel.com/about/) which promotes Calcium Channel research.
Dr Ben Whalley delivered an invited talk to the North East Epilepsy Research Meeting on 27th September entitled Cannabis and epilepsy: fact from fiction.
Dr Mark Dallas gave an invited talk to the European Network on Gasotransmitters at Exeter University on 8th September entitled 'Carbon monoxide regulation of the Kv2.1 channel'
The BBSRC have invited RSOPs Dr Che Connon to apply for the Innovator of the Year competition for his development of novel stem cell storage technology
Clinical Trials
Work investigating the therapeutic potential of non-psychoactive components of cannabis for the treatment of drug resistant epilepsy by RSOP staff, Dr Ben Whalley, Dr Gary Stephens and Dr Andre Cobb has reached human clinical trials and named patient use in paediatric epilepsies. In a press release (http://www.gwpharm.com/Phase1Epilepsy.aspx), sponsors GW Pharma said We are pleased to have advanced GWP42006 to first dose in man, a significant milestone in the development of this novel product candidate. The decision to progress into Phase 1 follows several years of highly promising pre-clinical research. We believe that GWP42006 has the potential to become an important advance in the treatment of epilepsy, a condition for which there remains a substantial unmet medical need. In addition to the Phase 1clinical trial that is now in progress, a different compound, cannabidiol, developed within RSOP as part of the same programme is now being used to treat intractable childhood epilepsy. Three expanded access INDs have recently been granted by the FDA to U.S. clinicians to allow treatment of a small number of paediatric epilepsy patients with a CBD formulation supplied by GW Pharma.
Dr Vitaliy Khutoryanskiy delivered talk entitled "New synthetic routes to thiolated mucoadhesive nanoparticles" at the 27th Conference of the European Colloid and Interface Society held in Sofia (Bulgaria) on 1st September in addition to an invited lecture "Microencapsulation of probiotics using alginates" at 1st UK Hydrocolloids symposium held at the University of Huddersfield on 10th September.